Pepdexpepdex
Stack
โ„– 024

Survodutide

A weight-loss drug built for a stronger fat-burn signal than GLP-1-only options. A dual agonist (GLP-1 + glucagon) from Boehringer Ingelheim / Zealand Pharma, where glucagon activation boosts metabolic rate.

Fat Loss
Evidence: Moderate

Survodutide: A weight-loss drug built for a stronger fat-burn signal than GLP-1-only options. A dual agonist (GLP-1 + glucagon) from Boehringer Ingelheim / Zealand Pharma, where glucagon activation boosts metabolic rate. Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide.

FDA โ“˜
Not approved
WADA
Not banned
Typical dose
Start 0.3 mg sub-q weekly
Half-life โ“˜
~6 days
Route โ“˜
Subcutaneous
Schedule
Once weekly
In plain English

Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.

Status & legalityWhat do these mean? โ†’
Natty? โ“˜
Not natty
FDA โ“˜
Not approved

Investigational. Phase 3 trials by Boehringer Ingelheim and Zealand Pharma (co-developers).

Compounding โ“˜
Investigational

In clinical trials, not yet approved for prescription.

WADA โ“˜
Not listed
Prescribed โ“˜

Not yet approved. Trial access only.

Who it's for

  • โ†’Users plateaued on GLP-1-only drugs
  • โ†’People targeting >15% body weight loss
  • โ†’Phase 2 / 3 trial-followers wanting cutting-edge

What to expect

  1. Week 1

    Appetite drops. Mild nausea. Slight body-temp uptick (glucagon thermogenesis).

  2. Week 4

    First titration step. ~3-6 lb down for most users.

  3. Week 8

    Cumulative loss building steadily. Phase 3 topline was ~16.6% at 76 weeks, below Retatrutide but well above GLP-1-only options.

Looking at Survodutide? Your next 3 steps

  1. 1Work out your syringe units

    Vial size + BAC water turns into the exact units to draw for Survodutide.

    Open calculator โ†’
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide โ†’
  3. 3Save it & ask the Coach

    A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.

    Create free account โ†’

How it works (mechanism)

GLP-1 + glucagon dual agonist (no GIP). Different combination than Retatrutide, pairs satiety with thermogenesis, skipping the GIP arm.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Nausea (especially titration steps)
02Diarrhea or constipation
03Mild fatigue
04Slightly elevated heart rate (glucagon effect)

When NOT to use

  • โš MTC / MEN-2 history
  • โš Pancreatitis history
  • โš Pregnancy / nursing
  • โš Severe cardiovascular disease

Bloodwork to monitor

  • โ€ข Lipid panel
  • โ€ข ALT/AST
  • โ€ข A1C

Common mistakes

  • โ€ข Titrating too fast
  • โ€ข Treating elevated HR as 'caffeine sensitivity'
  • โ€ข Not adjusting protein during the cut

What it actually is

Survodutide is an investigational weekly injection that activates two receptors, GLP-1 and glucagon. It comes from Boehringer Ingelheim and Zealand Pharma and is in late-stage development for obesity and for liver disease. It is not approved anywhere. Its distinguishing feature is that it leans on the glucagon arm rather than adding GIP the way tirzepatide does.

The GLP-1 half does what the whole class does: reduces appetite, slows stomach emptying, prompts glucose-dependent insulin release. The glucagon half is the difference. Glucagon is normally thought of as insulin's opposite, raising blood sugar, but it also increases energy expenditure and drives the liver to process stored fat. Pairing it with a GLP-1 signal is meant to add the burning side to the eating-less side, and it is also why liver disease is one of the lead indications and why resting heart rate goes up.

Forms, and which is which

Clinical trial supplyThe only lawful route

The only context where identity, dose and sterility are known, with monitoring attached.

Verdict: The only defensible access.

Products sold as survodutideNothing lawful

No approved product exists to compare against, so identity, potency and sterility rest entirely on the seller and cannot be checked.

Verdict: Unverifiable contents, outside any lawful supply route.

Blends with other incretin agentsNothing

Combines an unapproved compound with others and makes any effect or side effect unattributable.

Verdict: Several unknowns in one syringe.

Oral survodutideDoes not exist as an approved product

No approved oral form. What is in a product marketed as one cannot be verified.

Verdict: No approved oral form exists.

What it is claimed to do, graded

Weight loss in adults with obesityStrong

A randomised double-blind phase 2 trial in Lancet Diabetes and Endocrinology reported substantial weight reduction, and phase 3 trial records are indexed. Real evidence, and not yet an approval.

Improves MASH and liver fibrosisStrong

A phase 2 randomised trial in NEJM in 2024 showed improvement in MASH with fibrosis. This is one of the better-evidenced claims for any unapproved compound in this catalog.

Blood sugar control in type 2 diabetesModerate

Dose-response data on HbA1c is published. Smaller than the approved drugs' programmes.

Better tolerated than GLP-1-only drugsNone shown

No head-to-head trial supports this. Nausea in the trials was common and titration-dependent.

Safe for people with cardiovascular diseaseNone shown

The opposite is the live concern. The glucagon arm raises resting heart rate, and a dedicated cardiovascular outcome programme was designed precisely because that question is open.

Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.

Pros and cons

Pros
  • โ€ข Phase 2 randomised evidence in both obesity and MASH, published in Lancet and NEJM
  • โ€ข The glucagon arm targets liver fat directly, which is a real clinical problem
  • โ€ข Weekly dosing
  • โ€ข A cardiovascular outcome programme exists, which means the heart rate question is being answered rather than ignored
Cons
  • โ€ข Not approved anywhere
  • โ€ข Raises resting heart rate through the glucagon arm, and the long-term consequence is unresolved
  • โ€ข Nausea is common and titration steps are where it bites
  • โ€ข Nothing sold outside a trial has verifiable identity
  • โ€ข Glucagon activation can raise blood glucose, which complicates use in diabetes

When to stop

  • โ€ข Resting heart rate climbing and staying up, or palpitations at rest
  • โ€ข Severe persistent abdominal pain radiating to the back
  • โ€ข Vomiting that prevents keeping fluids down
  • โ€ข A new neck lump, hoarseness or difficulty swallowing
  • โ€ข Pregnancy

Interactions

Insulin or sulfonylureasCaution

The GLP-1 arm lowers glucose and the glucagon arm raises it, so the net effect is harder to predict than with a GLP-1-only drug.

Other GLP-class drugsAvoid

No added benefit, multiplied gastrointestinal effects.

StimulantsCaution

Survodutide raises heart rate. Adding stimulants compounds that.

Oral medications generallyMonitor

Delayed gastric emptying alters absorption rate. No approved interaction labelling exists to guide this.

Resistance training and adequate proteinCompatible

General weight-loss guidance extrapolated here, not a survodutide trial finding.

Is this for you?

Probably worth reading further if
  • โ€ข Participation in an authorised clinical trial is the only context in which this is lawfully available
  • โ€ข Anyone weighing it against the approved options with a clinician, on the published data
Skip it if
  • โ€ข You want an approved medicine
  • โ€ข You have cardiovascular disease or an arrhythmia โ€” the heart rate effect is the open question
  • โ€ข Personal or family history of medullary thyroid carcinoma or MEN-2
  • โ€ข You are pregnant or nursing

The one number

Phase 2 randomised trial in MASH with fibrosis published in NEJM, 2024
N Engl J Med, 2024 (PMID 38847460)

Sources for the claims above

Drug & supplement interactions

  • โš Insulin and sulfonylureas: dose reduction needed
  • โš Glucagon arm: monitor HR; caution with stimulants
  • โš Trial-only, full interaction profile not yet published

Community patterns

Members only
Free, no account needed

New to Survodutide? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Member answer
is 250mcg of bpc enough for a knee injury?
For a knee, is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. , run it , and don't drop below , results tend to fall off under that line. If nothing's moved by week 3, that's when earns its place.
how much bac water for a 10mg reta vial?
is the standard play for a 10 mg reta vial. That gives you , clean unit math across the whole titration: on a 100-unit insulin syringe. Run instead if you want fewer, more concentrated shots. Most people titrate up over , and that mix keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Numbers redacted in this preview. Members get the full answer, on their own stack.

Ask the Coach anything about Survodutide or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Unlock the full Coach, from $4.99/week โ†’

Frequently asked

What is Survodutide?+
Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.
Is Survodutide FDA approved?+
Investigational. Phase 3 trials by Boehringer Ingelheim and Zealand Pharma (co-developers).
Is Survodutide legal?+
Survodutide is not FDA-approved, so there is no approved prescription version. Most supply is sold as "research only" by peptide vendors. A compounding pharmacy may only use substances the FDA permits for compounding, and many research peptides are not permitted โ€” do not assume a compounded prescription is available. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is Survodutide banned by WADA?+
Survodutide is not currently on the WADA prohibited list.
Are you still natty after taking Survodutide?+
No. Survodutide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Survodutide?+
Not yet approved. Trial access only.
What's the typical dose of Survodutide?+
Dosing depends on your goal, experience, and tolerance. The full Survodutide protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of Survodutide?+
Common side effects include: Nausea (especially titration steps); Diarrhea or constipation; Mild fatigue; Slightly elevated heart rate (glucagon effect). Less common effects and full safety details are on the entry page.
How long until Survodutide starts working?+
Appetite drops. Mild nausea. Slight body-temp uptick (glucagon thermogenesis).
What can you stack with Survodutide?+
Survodutide is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get Survodutide?+
Pepdex does not sell, ship, or recommend suppliers. Survodutide is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.
Survodutide vs Mazdutide, which is better?+
Mazdutide vs Survodutide: two late-stage GLP-1 + glucagon dual agonists. Innovent vs Boehringer Ingelheim development paths. Full head-to-head comparison: https://pepdex.co/compare/mazdutide-vs-survodutide
Survodutide vs Retatrutide, which is better?+
Survodutide vs Retatrutide: dual GLP-1 + glucagon vs triple GLP-1 + GIP + glucagon. Two Phase 3 glucagon-arm compounds, weighed on obesity and fatty-liver disease (MASH). Full head-to-head comparison: https://pepdex.co/compare/survodutide-vs-retatrutide

Common questions about Survodutide

Head-to-head with Survodutide

Compare
Survodutide vs Mazdutide โ†’
Compare
Survodutide vs Retatrutide โ†’

Tracked alongside Survodutide

Same goal, different aisle โ€” each graded on its own evidence in the Pepdex catalog.

Whey protein โ†’
muscle preservation is the open question on any GLP-1 run
Electrolytes โ†’
appetite suppression cuts fluid and sodium intake with it
Fiber โ†’
the constipation answer that shows up in every GLP-1 thread
Metformin โ†’
the prescription neighbour people compare these protocols against

More in Fat Loss

โ„– 009
Tirzepatide

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

โ„– 010
Semaglutide

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

โ„– 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

โ„– 059
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.